Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $307.51 USD
Change Today +0.60 / 0.20%
Volume 1.1M
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

allergan plc (AGN) Snapshot

Open
$309.19
Previous Close
$306.91
Day High
$309.79
Day Low
$305.01
52 Week High
03/20/15 - $317.72
52 Week Low
08/12/14 - $201.91
Market Cap
120.7B
Average Volume 10 Days
2.1M
EPS TTM
$2.88
Shares Outstanding
392.4M
EX-Date
--
P/E TM
106.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALLERGAN PLC (AGN)

allergan plc (AGN) Details

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

21,600 Employees
Last Reported Date: 02/18/15
Founded in 1983

allergan plc (AGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Executive Chairman
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $31.4K
Executive Vice President and President of Gen...
Total Annual Compensation: $707.5K
Executive Vice President and President of Bra...
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2014.

allergan plc (AGN) Key Developments

Allergan plc, Kythera Biopharmaceuticals, Inc. - M&A Call

To discuss about definitive agreement under which Allergan has agreed to acquire KYTHERA in cash and equity transaction

Allergan plc Re-Affirms Earnings Guidance for the Year 2015

Allergan plc re-affirmed earnings guidance for the year 2015. The company announced 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a result of the acquisition. The acquisition is expected to be breakeven in 2016 and accretive thereafter.

Actavis plc has Changed its Name to Allergan plc

Actavis plc changed its name to Allergan plc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $307.51 USD +0.60

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $153.26 USD -1.73
Bristol-Myers Squibb Co $67.48 USD -0.19
Eli Lilly & Co $86.14 USD +1.29
Medtronic PLC $73.81 USD -0.27
Novo Nordisk A/S kr368.70 DKK -2.20
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 1.8x
Price/Cash Flow 140.4x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN PLC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.